JoVE Journal
Cancer Research
Cancer Research
A subscription to JoVE is required to view this content. Sign in or start your free trial.
Chapters
Summary
To expand the ability of laboratories worldwide to assess the eligibility of patients with lung cancer for treatment with pembrolizumab, in a reliable and reproducible manner, we developed an assay that uses the 22C3 antibody concentrate on a widely available immunohistochemical autostainer, for both biopsy and cytology specimens.